Nirvana Life Sciences
Is focused on developing medical.
Market cap
$2.7m
Enterprise valuation
$3m (Public information from Sep 2024)
Share price
CAD0.075 NIRV.CN
Vancouver British Columbia (HQ)
Financials
Estimates*
| CAD | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| EBITDA | (<1m) | (<1m) | 3.4m | (1.2m) |
| Profit | (<1m) | (<1m) | (5.7m) | (1.5m) |
| EV / EBITDA | - | - | 1.2x | -0.9x |
| R&D budget | - | - | <1m | <1m |
| Date | Investors | Amount | Round |
|---|---|---|---|
$450k | Early VC | ||
| N/A | N/A | IPO | |
* | N/A | Acquisition | |
| Total Funding | $450k | ||